THE FACT ABOUT DO-264 THAT NO ONE IS SUGGESTING

quinupristin/dalfopristin will raise the degree or effect of avanafil by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Observe. CYP3A4 inhibitors may well lower avanafil clearance rising systemic exposure to avanafil; elevated levels may perhaps end in enhanced linked adverse activities; the most encouraged dose of STENDRA is 5